What Is MAT (Medication‑Assisted Treatment)?

01 What MAT actually means — and the newer names

MAT is the umbrella term for treating a substance use disorder with an FDA-approved medication, usually combined with counseling or therapy. The medication addresses the biology — cravings, withdrawal, the brain circuits addiction hijacks — while the counseling addresses everything else.

The language is shifting: SAMHSA and many clinicians now say "medications for substance use disorders" or "MOUD" (medications for opioid use disorder), partly to stop implying the medication merely "assists" some other, realer treatment. If you see MAT, MOUD, or "pharmacotherapy" — it's the same territory.

02 The medications, by substance

Per SAMHSA, the FDA-approved options are:

• For opioid use disorder: methadone (dispensed through specially certified programs), buprenorphine (prescribable in regular office settings), and naltrexone (including a monthly injection).
• For alcohol use disorder: naltrexone, acamprosate, and disulfiram.

They work differently — some stabilize the system, some block effects, some create deterrents — and choosing between them is a medical decision made by the person and a qualified prescriber, based on their history and situation. We describe; we don't recommend.

03 What the evidence says

This is one of the best-studied corners of addiction treatment:

• A Cochrane review of methadone maintenance found it keeps people in treatment and suppresses illicit opioid use better than approaches without opioid-replacement medication.
• A Cochrane review of buprenorphine reached the same core conclusion: better retention and reduced illicit use compared with placebo.
• A BMJ systematic review and meta-analysis of cohort studies found that time in methadone or buprenorphine treatment was associated with substantially lower risk of death than time out of it — one reason clinicians treat staying on the medication as a safety issue, not just a preference.

None of this makes medication mandatory or right for everyone — it makes it a legitimate, first-line option that no one should be talked out of by stigma.

04 "Isn't that just trading one addiction for another?"

It's the most common worry families bring to MAT, and the research answer is no — because it conflates two different things. Physical dependence (the body adapting to a medication, as it does with many blood-pressure or antidepressant medications) is not addiction (compulsive use despite harm, loss of control, a life organized around the substance).

Someone on a stable, prescribed dose of buprenorphine — going to work, sleeping at home, rebuilding relationships — is not living the life addiction was giving them. As NIDA frames it, these medications relieve cravings and withdrawal without the destructive cycle. Recovery on medication is recovery.

05 How MAT fits with everything else

MAT isn't a level of care — it's a component that can run through every level. Someone can be on buprenorphine while attending an IOP, stepping down from a PHP, or living at home with weekly therapy. It also matters for co-occurring conditions: psychiatric medications and addiction medications are commonly managed together in dual-diagnosis care.

If you're helping someone compare programs, one revealing question is: "Do you support patients on MAT?" Programs that refuse evidence-based medication are telling you something about how they relate to the research. And if detox is on the table, read Detox at Home first — opioid and alcohol withdrawal carry real risks that medication-supported care exists to manage.

To find programs independently — including by medication offered — use the government-run FindTreatment.gov. In a crisis, call or text 988, or call 1‑800‑662‑HELP (4357) — SAMHSA's free, confidential, 24/7 helpline.